Efficacy and Safety of Palbociclib in Patients with Estrogen Receptor-positive/human Epidermal Growth Factor Receptor 2-negative Advanced Breast Cancer with Preexisting Conditions: A Post Hoc Analysis of PALOMA-2

Reshma Mahtani; Karen Gelmon; Janice M. Walshe; Anil A. Joy; Meghan S Karuturi; Patrick Neven; Dongrui Ray Lu; Sindy Kim; Patrick Schnell; Eustratios Bananis; Lee Schwartzberg

Efficacy and Safety of Palbociclib in Patients with Estrogen Receptor-positive/human Epidermal Growth Factor Receptor 2-negative Advanced Breast Cancer with Preexisting Conditions: A Post Hoc Analysis of PALOMA-2

Reshma Mahtani, Karen Gelmon, Janice M. Walshe, Anil A. Joy, Meghan S Karuturi, Patrick Neven, Dongrui Ray Lu, Sindy Kim, Patrick Schnell, Eustratios Bananis, Lee Schwartzberg

Miami Cancer Institute

Research output: Contribution to journal › Article › peer-review

Original language	American English
Journal	Breast
Volume	59
State	Published - 2021

Disciplines

Medicine and Health Sciences

Cite this

Mahtani, R., Gelmon, K., Walshe, J. M., Joy, A. A., Karuturi, M. S., Neven, P., Lu, D. R., Kim, S., Schnell, P., Bananis, E., & Schwartzberg, L. (2021). Efficacy and Safety of Palbociclib in Patients with Estrogen Receptor-positive/human Epidermal Growth Factor Receptor 2-negative Advanced Breast Cancer with Preexisting Conditions: A Post Hoc Analysis of PALOMA-2. Breast, 59.

@article{ebd1450232644e11a8e889c8732fbff1,

title = "Efficacy and Safety of Palbociclib in Patients with Estrogen Receptor-positive/human Epidermal Growth Factor Receptor 2-negative Advanced Breast Cancer with Preexisting Conditions: A Post Hoc Analysis of PALOMA-2",

author = "Reshma Mahtani and Karen Gelmon and Walshe, \{Janice M.\} and Joy, \{Anil A.\} and Karuturi, \{Meghan S\} and Patrick Neven and Lu, \{Dongrui Ray\} and Sindy Kim and Patrick Schnell and Eustratios Bananis and Lee Schwartzberg",

note = "Randomized Controlled Trial doi: 10.1016/j.breast.2021.07.017. 1 British Columbia Cancer Agency, Vancouver, BC, Canada. Electronic address: [email protected]. 2 Cancer Trials Ireland, Dublin, Ireland. 3 Sylvester Cancer Center, University of Miami, Deerfield Beach, FL, USA. 4 Cross Cancer Institute, Edmonton, AB, Canada. 5 MD Anderson Cancer Center, Houston, TX, USA.",

year = "2021",

language = "American English",

volume = "59",

journal = "Breast",

}

TY - JOUR

T1 - Efficacy and Safety of Palbociclib in Patients with Estrogen Receptor-positive/human Epidermal Growth Factor Receptor 2-negative Advanced Breast Cancer with Preexisting Conditions: A Post Hoc Analysis of PALOMA-2

AU - Mahtani, Reshma

AU - Gelmon, Karen

AU - Walshe, Janice M.

AU - Joy, Anil A.

AU - Karuturi, Meghan S

AU - Neven, Patrick

AU - Lu, Dongrui Ray

AU - Kim, Sindy

AU - Schnell, Patrick

AU - Bananis, Eustratios

AU - Schwartzberg, Lee

N1 - Randomized Controlled Trial doi: 10.1016/j.breast.2021.07.017. 1 British Columbia Cancer Agency, Vancouver, BC, Canada. Electronic address: [email protected]. 2 Cancer Trials Ireland, Dublin, Ireland. 3 Sylvester Cancer Center, University of Miami, Deerfield Beach, FL, USA. 4 Cross Cancer Institute, Edmonton, AB, Canada. 5 MD Anderson Cancer Center, Houston, TX, USA.

PY - 2021

Y1 - 2021

UR - https://pubmed.ncbi.nlm.nih.gov/34388698/

M3 - Article

VL - 59

JO - Breast

JF - Breast

ER -

Efficacy and Safety of Palbociclib in Patients with Estrogen Receptor-positive/human Epidermal Growth Factor Receptor 2-negative Advanced Breast Cancer with Preexisting Conditions: A Post Hoc Analysis of PALOMA-2

Disciplines

Other files and links

Cite this